Health ❯ Healthcare

Clinical Trials

Drug Development Phase 3 Trials Drug Efficacy Patient Outcomes Phase III Trials Randomized Controlled Trials Research Studies Cancer Research Efficacy Studies Drug Approval

Once-Daily GLP-1 Pill Delivers Nearly 10% Weight Loss in Phase 3 Trial of Adults With Diabetes

The oral small molecule orforglipron offers a refrigeration-free option that could widen access to incretin therapy if regulators approve it.

Prime Editing Tool PERT Debuts as Broad, One-Time Strategy for Nonsense Mutations

FDA OKs RVO Use and Monthly Dosing for Regeneron’s Eylea HD

FDA Approves Koselugo for Adults With NF1-Related Plexiform Neurofibromas

City of Hope Completes $1.5 Billion Irvine Cancer Hospital, First Patients Arrive Dec. 1

Stories older than 24h

Protara Reports Strong Interim Phase 2 Results for TARA-002 in Pediatric Lymphatic Malformations

Agios’ Sickle Cell Pill Lifts Hemoglobin but Misses Pain-Crisis Goal in Phase 3

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

Sorfequiline Outperforms Standard TB Regimens in Phase 2 Trial

Olema Soars on Roche SERD Win, Then Slips on Planned Stock Offering

Study Finds NIH Cut Funding to 383 Clinical Trials, Affecting 74,000 Participants

Roche Says Breast Cancer Pill Cuts Recurrence in Phase 3 Adjuvant Trial

Nuvalent Reports 31% ORR in Pretreated, 86% in Untreated ALK+ NSCLC With Neladalkib

Zymeworks Shifts to Royalty Model After Ziihera’s Phase 3 Win in HER2‑Positive Gastroesophageal Cancer

Study Identifies TSP‑1–CD47 Signal That Drives T‑Cell Exhaustion in Cancer

FDA Adds Boxed Liver Warning and Limits Elevidys to Ambulatory Boys 4 and Up

EMA Panel Backs Higher-Dose Spinraza for 5q SMA

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

FDA Approves Komzifti, First Menin Inhibitor for Relapsed NPM1‑Mutant AML

FDA Approves Poherdy as First Interchangeable Biosimilar to Perjeta for HER2-Positive Breast Cancer